J&J, Basilea To Base Ceftobiprole Filing For Hospital-Acquired Pneumonia On Phase III Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite positive results in patients with hospital-acquired pneumonia, the Phase III study failed to demonstrate non-inferiority in a high-risk subgroup.
You may also be interested in...
J&J/Basilea’s Ceftobiprole NDA Edges Ahead
“Approvable” word from FDA represents a victory in tough antibiotic field.
J&J/Basilea’s Ceftobiprole NDA Edges Ahead
“Approvable” word from FDA represents a victory in tough antibiotic field.
FDA Wants More Ceftobiprole Data From J&J/Basilea
Racing against Theravance's "approvable" telavancin, company will supply added results in diabetic foot infections.